Compare Fox Corp Class B (FOX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Pfizer Inc — how do they compare? Fox Corp Class B trades at $59.02 (market cap $25.36B), while Pfizer Inc trades at $27.81 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 6.3× Fox Corp Class B's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Pfizer Inc for 158 Days on average.
| FOX | PFE | |
|---|---|---|
Market Cap | $25.36B | $158.56B |
Volume | 886,620 | 44,138,282 |
Sector | Media | Health |
52-Week High | $67.76 | $29.02 |
52-Week Low | $44.39 | $23.67 |
Typical Hold Time | 75 Days | 158 Days |
Enterprise Value | $28.72B | $210.06B |
Dividend Yield | 1.02% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.98, up 0.72% today, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026, alongside a net income margin of 13.88% in 2025, highlight robust profitability. The company maintains solid cash flow and a healthy balance sheet with $5.35B in cash. Analyst consensus is a Buy with a $84.75 price target, though technical indicators show resistance near $57.
The stock presents a value opportunity with a P/E of 14.59 and P/S of 1.44, supported by earnings growth. Risks include a projected net cash flow decline to -$1.1B in 2026 and bearish technical trends. Upside potential exists if the company meets Q3 2026 EPS expectations of 2.06, but investors should monitor cash flow trends and competitive pressures in the media sector.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
